Abstract
Roxithromycin, statins, and metformin show promise for potentially limiting abdominal aortic aneurysm (AAA) expansion. However, findings are constrained by methodological limitations such as study design and sample size, necessitating future validation via high-quality randomized controlled trials (RCTs).
Introduction
Abdominal aortic aneurysm (AAA) is a chronic degenerative condition where the aorta weakens and dilates. Often termed a "silent killer," it typically remains asymptomatic until a life-threatening rupture occurs. Currently, for aneurysms below the surgical threshold (typically <50-55mm), the standard of care is "watchful waiting" via serial imaging. There are no FDA-approved pharmacological treatments to arrest or slow AAA progression, leaving high-risk surgical repair as the only definitive option once the aneurysm reaches a critical size.
Methodology
This study utilized a Bayesian Network Meta-Analysis (NMA) to synthesize data from existing literature. Unlike traditional meta-analyses that rely on direct head-to-head comparisons, an NMA allows for indirect statistical estimations between treatments that have not been compared directly in a single trial.
Study Selection
The researchers screened major databases including PubMed, Embase, Web of Science, and the Cochrane Library. The selection process followed the PRISMA guidelines to ensure a rigorous and transparent review of the evidence.
The final analysis included 11 RCTs (comprising 2,135 patients) and 13 cohort studies. Efficacy was measured using Standardized Mean Difference (SMD) and ranked using SUCRA (Surface Under the Cumulative Ranking curve) values.
Study Characteristics
The included RCTs evaluated a variety of pharmacological classes, including antibiotics (doxycycline, roxithromycin), antihypertensives (perindopril, amlodipine, telmisartan), and metabolic agents (metformin).
Key Insights and Results
The Antibiotic Surprise
Roxithromycin, a macrolide antibiotic, emerged as the top performer in the RCT network with a SUCRA value of 0.973. It significantly reduced AAA growth velocity with an SMD of 0.39 [95% CrI: -0.69 to -0.10]. This benefit is likely due to its anti-inflammatory properties rather than its antibacterial action, as inflammation is a primary driver of aortic wall degradation.
The Observational-Experimental Gap
A notable discrepancy exists between study types regarding statins and metformin. While cohort studies consistently link these drugs to slower expansion (e.g., 1.1 mm/y growth for metformin users vs. 1.6 mm/y for non-users), RCT evidence remains weak or non-significant. This suggests potential "indication bias" in observational data, where patients on these medications may simply be receiving better overall cardiovascular care.
Ineffective Interventions
Despite AAA being a vascular disease, common blood pressure medications like perindopril and amlodipine showed no significant benefit in slowing growth. Furthermore, doxycycline, once considered a promising candidate for its ability to inhibit matrix metalloproteinases (MMPs), failed to show significant benefits across the pooled RCT data.
Limitations and Future Directions
The findings are subject to several constraints:
- Sample Size: The roxithromycin results are based on only two relatively small trials.
- Follow-up Duration: Most studies lasted only 1.5 to 2.5 years, which may be insufficient to capture the long-term trajectory of slow-growing aneurysms.
- Heterogeneity: Variations in imaging modalities (Ultrasound vs. CT) and measurement planes introduced noise into the data.
There is an urgent need for high-quality, multi-center RCTs specifically targeting statins and metformin. Future research may also explore mesenchymal stem cell (MSC) therapy and targeted nanomaterial-based drug delivery as the next frontiers in non-surgical AAA management.
Summary updated